EP.12H.02 Amivantamab, An EGFR-MET Bispecific Antibody, with Cetrelimab, An Anti-PD-1 Antibody, In Advanced NSCLC: Phase 1/2 PolydamasP.J. Voon, B.C. Cho, Christine Baudelet et al.|Journal of Thoracic Oncology|2024Cited by 1